Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2015

01-04-2015 | Letter to the editor

Author response to “Scientific rigour is far more than a matter of sample size”

Author: Michael W. Rabow

Published in: Supportive Care in Cancer | Issue 4/2015

Login to get access

Excerpt

Although we appreciate the comments offered by Pär Salander, a number of points require clarification. The limitations of our study were described explicitly in the published discussion of our results. Nowhere do we suggest that a large sample size is a substitute for scientific rigor. Our study used a convenience sample to begin to explore an important but understudied element of clinical palliative care. …
Metadata
Title
Author response to “Scientific rigour is far more than a matter of sample size”
Author
Michael W. Rabow
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2609-9

Other articles of this Issue 4/2015

Supportive Care in Cancer 4/2015 Go to the issue

Original Article

Comparison of the acceptability and benefits of two mindfulness-based interventions in women with breast or gynecologic cancer: a pilot study

Original Article

Heterosexual couples and prostate cancer support groups: a gender relations analysis

Letter to the editor

The role of the OncPal deprescribing guideline in end-of-life care

Original Article

The initial clinical interview—can it reduce cancer patients’ fear?

Original Article

Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study

Original Article

Risk-reduction opportunities in breast cancer survivors: capitalizing on teachable moments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits